Patients with atrial fibrillation receiving the factor XI inhibitor abelacimab have a lower risk for bleeding than those ...

The National Institutes of Health (NIH) on Tuesday discontinued the low-dose rivaroxaban arm of its ongoing Phase 3 CAPTIVA ...

BOSTON, MA—For patients undergoing transradial coronary procedures, a short course of rivaroxaban (Xarelto; Bayer/Janssen) reduces the rate of radial artery occlusion without significantly increasing ...

Perugia, Italy - Promising phase 2 results with the new oral direct factor Xa inhibitor anticoagulant rivaroxaban (Bayer) in the treatment of patients with deep vein thrombosis (DVT) have been ...

LAS VEGAS, NV—The first day of VIVA 2017 began with some timely insights into pharmacotherapy with non-vitamin K oral anticoagulants (NOACs) in patients with deep vein thrombosis (DVT), and a look ...

Please provide your email address to receive an email when new articles are posted on . “The mortality benefit demonstrated in the COMPASS trial ... is externally consistent with prior evidence of a ...

WASHINGTON -- Continuing use of rivaroxaban (Xarelto) at either 20 mg or 10 mg dose appears to reduce the risk of recurrent venous thromboembolism without increasing the risk for bleeding. "This is a ...

Please provide your email address to receive an email when new articles are posted on . The currently available anticoagulants are hampered by many drawbacks. These include substantial interpatient ...

An anti-stroke drug touted as more effective than older blood thinners may be riskier than doctors and patients have been led to believe. Data has shown that the drug rivaroxaban may be significantly ...

Rivaroxaban, a direct oral anticoagulant (DOAC), demonstrated greater efficacy and similar safety compared with warfarin in patients with chronic kidney disease and atrial fibrillation. Rivaroxaban, a ...

The oral anticoagulant rivaroxaban is a safe and effective alternative to vitamin K antagonists for patients with atrial fibrillation (AF) undergoing cardioversion. This finding from the X-VeRT trial ...

The Appraisal Committee considered evidence submitted by the manufacturer of rivaroxaban and a review of this submission by the Evidence Review Group (ERG). The manufacturer's submission compared ...